WONBIOGEN CO LTD
WONBIOGEN is a Korean medical device manufacturer of moist wound care dressings and medical device cosmetics. It sells through OEM/ODM partnerships with Korean pharma companies and proprietary MEDISORB and THERASORB brands, exporting to 35+ countries.
- Company typePublic
- Founded2006
- HeadquartersGyeongsan, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What WONBIOGEN CO LTD does
WONBIOGEN CO LTD is a South Korean medical device manufacturer specializing in moist wound care technology and highly biocompatible medical macromolecules. Founded in 2006 by CEO Kim Won-il at Kumoh National Institute of Technology's startup incubator and headquartered in Gumi-si, Gyeongsangbuk-do, the company develops, manufactures, and sells polyurethane foam dressings, hydrocolloid dressings, silver-containing antimicrobial dressings, silicone scar management products, and a medical device cosmetics line under proprietary brands including MEDISORB, THERASORB, RENODERM, REMSCAR, and HIPERSKIN.
The company operates a dual-track business model. The first leg is OEM/ODM manufacturing for three major Korean pharmaceutical companies — IlDong Pharmaceutical (Meditouch), Chong Kun Dang (SolSol Plus), and Daewoong Pharmaceutical (Cureban) — under their respective consumer brands. The second leg is proprietary brand sales to hospitals, clinics, wound care centers, and end consumers via Naver Smart Store and medical distribution channels. Underlying technology centers on moist wound environment maintenance through vapor-permeable polyurethane films and porous foam coatings that absorb exudates while blocking external bacteria and water, with a proprietary in-house roll-type production process developed in 2017 that replaced German equipment dependency.
WONBIOGEN has been KOSDAQ-listed (ticker: 307280) since January 2021 following a SPAC merger with Kyobo 8호기업인수목적회사, employs 140+ people, and exports to 35+ countries. Revenue reached approximately 300억 KRW as referenced in 2025 management commentary, up from 100억 KRW in 2016. The company is pursuing CE MDR certification by 2026 for Therasorb and Renoderm products to access North American and European markets, while expanding into medical device cosmetics through the Medisorb brand and a strategic investment in J&K Cosmetics (BONABELLA, L:MOT, BALANSKIN).
WONBIOGEN CO LTD firmographics
Firmographics- Name
- WONBIOGEN CO LTD
- Legal name
- WONBIOGEN Co., Ltd
- Website
- https://wonbiogen.co.kr
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- WONBIOGEN is a Korean medical device manufacturer of moist wound care dressings and medical device cosmetics. It sells through OEM/ODM partnerships with Korean pharma companies and proprietary MEDISORB and THERASORB brands, exporting to 35+ countries.
- Ownership category
- akta.pro rank
WONBIOGEN CO LTD industry classification
Industry- Product category
- Wound Care Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Wound Care & Ulcer Management (HLAKACAN)
- akta.pro secondary industries
- First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where WONBIOGEN CO LTD is headquartered
LocationHeadquarters
- HQ city
- Gyeongsan
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
WONBIOGEN CO LTD business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Wound Care Products OEM/ODM: Manufacturing wound care products under OEM/ODM arrangements for major pharmaceutical companies including IlDong Pharmaceutical (Meditouch brand), Chong Kun Dang (SolSol Plus brand), and Daewoong Pharmaceutical (Cureban brand). Currently represents a significant portion of revenue.
- Proprietary Brand Products: Sales of proprietary brand products including Therasorb, Renoderm, Medisorb, and Remscar directly to markets. The company aims to increase the proportion of proprietary brand (Therasorb) sales.
- Medical Device Cosmetics (MD): Sales of medically-certified cosmetic products under Medisorb brand including creams, gels, foot creams, and functional cosmetics launched in 2024-2025.
- Investment in J&CoS: Strategic investment in J&CoS for cosmetics business expansion under brands including Bonabella premium cosmetics, opening distribution through Lotte Duty Free.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
WONBIOGEN CO LTD product offering
Product offeringCore offering
WONBIOGEN manufactures moist wound care medical devices and medical device cosmetics, including polyurethane foam dressings, hydrocolloid dressings, silicone adhesive dressings, and silicone scar management products. The company sells under its own proprietary brands (Medisorb, Therasorb, Renoderm, Remscar, Hiperskin) and provides OEM/ODM contract manufacturing of wound care products for major Korean pharmaceutical companies such as Ildong Pharmaceutical (Meditouch), Chong Kun Dang (SolSol Plus), and Daewoong Pharmaceutical (Cureban).
Product overview
WONBIOGEN is a medical device manufacturer specializing in moist wound care products and medical device cosmetics. The company operates two main product strategies: (1) proprietary brands including MEDISORB (premium wound care with silver foam and silicone dressings), THERASORB (polyurethane foam dressings), RENODERM (hydrocolloid dressings and spot patches), REMSCAR (silicone scar management), and HIPERSKIN (skin care); and (2) ODM/OEM partnerships with pharmaceutical companies for wound dressing products under brands like Meditouch (Ildong), SolSol Plus (Chong Kun Dang), and Curepan (DaeWon). Additionally, the company manufactures and markets Medisorb MD medical device cosmetics certified by Korea Medical Device Safety Information Agency, including creams, gels, and sprays for skin barrier protection.
Differentiator
Problem solved
Functional benefit
Brands
- MEDISORB: Primary medical device brand covering polyurethane foam dressings, hydrocolloid dressings, and silver-containing wound care products. Products include Medisorb AG+, Medisorb Border Lite, and Medisorb H.
- THERASORB
- RENODERM
- HIPERSKIN
- REMSCAR
- 메디솝 (Medisorb)
Products and services
- MEDISORB Wound Care Dressings
Quantifiable outcome
- Wound healing accelerated with no scarring through moist environment maintenance
- +2 more outcomes
Companies that use WONBIOGEN CO LTD
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
WONBIOGEN CO LTD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
WONBIOGEN CO LTD partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- MR Innovation (엠알이노베이션)corePartnership for medical device cosmetics business with MR Innovation's aesthetic brand THESERA, following WONBIOGEN's investment in J&CoS for BONABELLA premium cosmetics brand. Both partnerships aimed at expanding into derma-cosmetics and medical device cosmetics market.
- J&CoS (제이앤코스)coreWONBIOGEN invested directly in J&CoS to expand into medical device cosmetics and functional cosmetics markets under brands including BONABELLA premium cosmetics. J&CoS operates cosmetic, eco-friendly living, and inner beauty health functional food businesses. Products launched through Lotte Duty Free.
- Medways (Germany)minorGerman medical device trading partner visit to WONBIOGEN for business discussions and factory tour. Medways represents WONBIOGEN's interests in European markets, with previous interest from German Ambassador Hans-Ulrich Sieder in WONBIOGEN's moist dressing materials and Surgicura anti-adhesion film technology.
- Samsung Pharmaceutical (삼성제약)minorPartnership with Samsung Pharmaceutical to develop and launch moist wound dressing 'Esca' series products under co-development arrangement.
- Innopass (이노패스)minorExport trading partner for Asian market distribution, handling exports to China and other Asian countries.
- Seoul Samsung HospitalcoreClinical trial partnership for Surgicura anti-adhesion film product. Currently conducting clinical trials on colorectal cancer (laparoscopic surgery) patients, with 35 of 70 subjects completed.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
WONBIOGEN CO LTD competitors and assessment
Company assessmentDirect peers
- Mölnlycke Health Care: Swedish global leader in advanced wound care dressings (Mepilex, Mepitel) and surgical solutions. Most direct comparability to WONBIOGEN's Therasorb foam and Renoderm hydrocolloid franchises in terms of product category and clinical positioning.
- ConvaTec Group: UK-listed global medical products company with major Advanced Wound Care segment (Aquacel, Foam Lite). Comparable product mix in hydrocolloid and foam dressings, similar OEM/private-label dynamics, and comparable regulatory pathways.
- Smith+Nephew: Global medical device company with substantial Advanced Wound Management portfolio (Allevyn, Acticoat). Overlaps directly with WONBIOGEN's foam and silver-antimicrobial dressing categories and shares the same hospital-procurement channel.
- Coloplast: Danish global medtech company with a dedicated Wound & Skin Care division (Biatain, Comfeel). Closely comparable in foam and hydrocolloid product portfolio and in serving both clinical and consumer/OEM channels.
- Paul Hartmann Group: German medical and hygiene products manufacturer with strong wound care portfolio (Hydrofilm, Cosmopor). Comparable in foam and hydrocolloid categories and has overlapping presence in Korea via established export channels.
- Genewel (Genewell): South Korean advanced wound care and dermatology company (Medifoam, Oasis). Closest domestic peer to WONBIOGEN with similar moist wound care technology, OEM business model, and Korean pharma customer base.
- Urgo Medical: French advanced wound care specialist (UrgoStart, Urgocell). Direct competitor in moist wound management with comparable product positioning and similar regulatory/market entry profile in Europe.
Broad incumbents
- 3M Health Care: Diversified global healthcare giant whose Medical Solutions division includes Tegaderm and other wound care dressings. Overlaps with WONBIOGEN in foam and transparent film categories but operates across a much broader medtech portfolio.
- Medline Industries: Largest privately held medical manufacturer and distributor in the US, with a sizable wound care portfolio (Optifoam, Opticell). Competes with WONBIOGEN on OEM/private-label foam and hydrocolloid dressings at scale.
Regional players
- Atopalm: South Korean medical device cosmetics brand specializing in ceramide-based skincare for sensitive skin. Closest regional comparable to WONBIOGEN's Medisorb MD line in the medical-cosmetics adjacency and channel overlap (Naver Smart Store, duty-free).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
WONBIOGEN CO LTD social profiles
Digital presenceWONBIOGEN CO LTD compliance and trust
Trust signalCompliance3 records
WONBIOGEN CO LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
WONBIOGEN CO LTD leadership team
Management profileNumber of profiles
Profiles6 records
WONBIOGEN CO LTD subsidiaries and ownership
Company hierarchySubsidiaries1 record
WONBIOGEN CO LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WONBIOGEN CO LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WONBIOGEN CO LTD
What does WONBIOGEN CO LTD do?
WONBIOGEN manufactures moist wound care medical devices and medical device cosmetics, including polyurethane foam dressings, hydrocolloid dressings, silicone adhesive dressings, and silicone scar management products. The company sells under its own proprietary brands (Medisorb, Therasorb, Renoderm, Remscar, Hiperskin) and provides OEM/ODM contract manufacturing of wound care products for major Korean pharmaceutical companies such as Ildong Pharmaceutical (Meditouch), Chong Kun Dang (SolSol Plus), and Daewoong Pharmaceutical (Cureban).
Is WONBIOGEN CO LTD a public or private company?
WONBIOGEN CO LTD is a public company. It is classified as public and is currently operating.
When was WONBIOGEN CO LTD founded?
WONBIOGEN CO LTD was founded in 2006. It employs 1 to 10 people.
Where is WONBIOGEN CO LTD based?
WONBIOGEN CO LTD is headquartered in Gyeongsan, South Korea, in the Asia region.
How does WONBIOGEN CO LTD make money?
Four revenue lines are on record. Wound Care Products OEM/ODM is the primary driver. The others are proprietary Brand Products, medical Device Cosmetics (MD) and investment in J&CoS.
Who are WONBIOGEN CO LTD's main competitors?
Direct peers on record are Mölnlycke Health Care, ConvaTec Group, Smith+Nephew, Coloplast, Paul Hartmann Group, Genewel (Genewell) and Urgo Medical. Broad incumbents are 3M Health Care and Medline Industries. Atopalm is listed as a regional player.
Does WONBIOGEN CO LTD have an API?
No public API is recorded for WONBIOGEN CO LTD.
What industry is WONBIOGEN CO LTD in?
WONBIOGEN CO LTD's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management, with a secondary code of CRADAMAB, First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care). Its NAICS code is 339113 and its SIC code is 3842.